Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill aims to knock out gout pain within hours

NCT ID NCT07706777

Symptom relief Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study tests an experimental drug called HRS-2129 in adults experiencing a sudden, painful gout flare. The goal is to see if it can safely reduce joint pain within 24 hours compared to a placebo. Researchers are also looking at how well different doses work and how quickly pain disappears.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called HRS-2129
What this could lead to
If successful, HRS-2129 could offer a new option for quickly easing the intense pain of a gout flare.
What could go wrong
This is an early phase 2 trial with only 90 participants, so results may not apply broadly. The drug's safety and effectiveness are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. Subjects requiring Acute gouty arthritis 3. Target joint VAS pain score ≥ 50 mm (screening) Exclusion Criteria: 1. Subjects with a history of severe allergies 2. Subjects with nervous system disease 3. Subjects with a history of mental illness 4. Subjects with abnormal liver and renal function 5. Subjects with poorly controlled hypertensive 6. QTc：\>450ms（male），\>470ms（female） 7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 8. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute gouty arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute gouty arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510630, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.